ABCL · AbCellera Biologics Inc.
$10.89
+4.11% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-14.6
Dividend yield
—
Beta
1.32
Avg volume
7M
Employees
1K
Daily Change %
4.11%
5 Days Change
-3.32%
10 Days Change
-3.75%
30 Days Change
13.22%
60 Days Change
62.50%
Month to Day Change
-2.04%
Year to Day Change
223.10%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ABCL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-11
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-11 | Truist Securities | Maintains | Buy | $12.00 → $30.00 |
| 2026-08-06 | Stifel | Maintains | Buy | $8.00 → $9.00 |
| 2026-08-06 | Cantor Fitzgerald | Maintains | Overweight | $11.00 → $12.00 |
| 2026-07-07 | Benchmark | Upgrade | Hold → Buy | $0.00 → $11.00 |
| 2026-05-05 | Cantor Fitzgerald | Initiates | Overweight | $0.00 → $7.00 |
| 2026-04-10 | Jones Trading | Initiates | Buy | $0.00 → $11.00 |
| 2025-11-07 | Leerink Partners | Downgrade | Outperform → Market Perform | $0.00 → $4.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 25.6% above the 50-day MA ($8.67).
- Price vs 200-day MA: Trading 106.2% above the 200-day MA ($5.28).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.29) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($2.78) and high ($12.50).
ABCL Price Chart
Loading chart for ABCL…
Fundamentals
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.